Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma

Launched by COSMETIQUE ACTIVE INTERNATIONAL · Feb 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a new treatment for facial melasma, a condition that causes dark patches on the skin. Researchers want to see how well this new product works compared to a standard treatment called cysteamine 5%. The trial will last for 4 months and will take place during a time of year when there is less sunlight to avoid any effects from sun exposure.

To participate in this study, you must have facial epidermal melasma and should not have any other active skin conditions like acne or cuts on your face. You also cannot be using certain birth control methods or have had any skin lightening treatments in the last 8 weeks. If you are eligible, you will be randomly assigned to receive either the new treatment or the standard one, and you will be monitored throughout the trial to see how your skin responds. This study is currently looking for participants of all genders, aged between 18 and 62.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Facial epidermal melasma (exclude mixed and dermal melasma)
• • Subjects free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face
• Exclusion Criteria:
• • Subjects with any other signs of significant irritation or skin disease
• • Subjects using oral contraceptive pills or hormonal implants as birth control measures during the study
• • Subjects who had a skin lightening procedure in the past 8 weeks